TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer

Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate

(2022) Rosemina Merchant et al.   Journal for ImmunoTherapy of Cancer

Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression

(2022) Christopher J. Nirschl et al.   Cancer Immunology Research

Function of γδ T cells in tumor immunology and their application to cancer therapy

(2021) Jang Hyun Park et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

MDNA11 is a long-acting IL-2 superkine that potentiates durable immune response in mouse tumor models and non-human primates.

(2021) Minh D. To et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys

(2021) Jared E. Lopes et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

An engineered IL-2 reprogrammed for anti-tumor therapy using a semi-synthetic organism

(2021) Jerod L. Ptacin et al.   Nature Communications

Pharmacokinetics of 40 kDa Polyethylene glycol (PEG) in mice, rats, cynomolgus monkeys and predicted pharmacokinetics in humans

(2021) Nidhi Sharda et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

16 Tumor growth inhibition mediated by a single dose of intratumoral TransCon™ TLR7/8 agonist was associated with activated circulating T and B cells and sustained low levels of systemic cytokines

(2021) Amer Mirza et al.   Journal for ImmunoTherapy of Cancer

769 A single dose of intratumoral TransCon™ TLR7/8 agonist monotherapy promoted sustained activation of antigen presenting cells resulting in CD4+ and CD8+ T cell activation and tumor growth inhibition

(2021) Luis Zuniga et al.   Journal for ImmunoTherapy of Cancer

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors

(2020) Wenyan Zhong et al.   BMC GENOMICS

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

(2020) Jared E Lopes et al.   Journal for ImmunoTherapy of Cancer

1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1)

(2020) U.N. Vaishampayan et al.   ANNALS OF ONCOLOGY

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

(2019) Zsolt Sebestyen et al.   NATURE REVIEWS DRUG DISCOVERY

IL-2 and Beyond in Cancer Immunotherapy

(2018) John M. Wrangle et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

(2017) Christian Klein et al.   OncoImmunology

The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency

(2017) Kennett Sprogøe et al.   Endocrine Connections

Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy

(2017) Deborah Charych et al.   PLoS One

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

(2016) D. H. Charych et al.   CLINICAL CANCER RESEARCH

Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy

(2014) F. Van Gool et al.   BLOOD

The IL-2 cytokine family in cancer immunotherapy

(2014) Geok Choo Sim et al.   CYTOKINE & GROWTH FACTOR REVIEWS

The immune synapse clears and excludes molecules above a size threshold

(2014) Adam N. R. Cartwright et al.   Nature Communications

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

(2013) Geok Choo Sim et al.   JOURNAL OF CLINICAL INVESTIGATION

Human IL-2 Mutein with Higher Antitumor Efficacy Than Wild Type IL-2

(2013) T. Carmenate et al.   JOURNAL OF IMMUNOLOGY

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

(2010) C. Krieg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA